Huons Meditech gains foothold in China following approval of aesthetic device

Huons Meditech's Premium 9Pin Needle / Courtesy of Huons Meditech

Huons Meditech is expanding into China’s fast-growing market for cosmetic procedures after securing regulatory clearance for a specialized injection needle designed for skin booster treatments, the company said Wednesday.

The Korea-based medical device firm said it recently completed registration with China’s National Medical Products Administration (NMPA) for its Premium 9Pin Needle, marking a key step in expanding its presence in the country.

The specialized needle is designed for use with the company’s proprietary injection systems, the Dermashine Pro and Dermashine Balance.

The company said the Premium 9Pin Needle features a precision-engineered structure that enhances stability even under high-pressure injection. The design also optimizes the needle’s inner diameter length, allowing high-viscosity substances to be delivered deep into the skin without leakage, reducing drug loss.

The medical device maker also said it improved convenience for both patients and practitioners, with a specialized bevel design that minimizes pain and recovery time and a dedicated protective cap to help prevent needle-stick injuries during procedures.

Huons Meditech said the approval will serve as a springboard to expand its share in the global market for cosmetic procedures, including China, while continuing to introduce innovative medical devices.

"By combining the globally recognized Dermashine platform with the innovative Premium 9Pin Needle, we have built a complete aesthetic treatment solution," Huons Meditech CEO Ha Chang-woo said. "With NMPA approval, we aim to strengthen our position as a trusted partner among aesthetic professionals in China," he added.

This article was published with the assistance of generative AI and edited by The Korea Times.